BioNTech (BNTX) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bio-Techne (TECH) has outperformed BioNTech (BNTX) over the past year, gaining 22.5% versus a loss of 10.2%. Over five years, TECH leads with a -41.7% price change compared with -61.5% for BNTX. BioNTech is the larger company by market cap ($23.93 billion vs $11.37 billion), about 2.1 times the size.
Bio-Techne pays a dividend yielding 0.44%, while BioNTech does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | TECH |
|---|---|---|
| Share price | $95.25 | $72.53 |
| Market cap | $23.93B | $11.37B |
| 1-day change | -0.50% | +0.14% |
| YTD return | +0.05% | +23.33% |
| 1-year return | -10.19% | +22.54% |
| 5-year return | -61.54% | -41.75% |
| P/E ratio (TTM) | — | 62.53 |
| Forward P/E | — | 31.36 |
| EPS (TTM) | $-7.79 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | — | $1.22B |
| Revenue growth (YoY) | — | -0.38% |
| Net income (latest FY) | — | $181.86M |
| Gross margin | — | 65.77% |
| Operating margin | — | 20.73% |
| Net margin | — | 14.97% |
| 52-week high | $124.00 | $72.69 |
| 52-week low | $79.52 | $43.20 |
| Distance from 52-week high | -23.19% | -0.22% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +21.56% | -2.80% |
| Average volume | 1.16M | 3.08M |
| Shares outstanding | 251.20M | 156.82M |
| Employees | 7,807 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.1 times larger than Bio-Techne by market value ($23.93B vs $11.37B).
- TECH has outperformed BNTX by 32.7 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
BNTX vs TECH FAQ
Which is bigger, BioNTech or Bio-Techne?
BioNTech (BNTX) is larger, with a market capitalization of $23.93B compared with $11.37B for Bio-Techne (TECH).
Which stock has performed better over the past year, BNTX or TECH?
TECH returned +22.54% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BioNTech or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while BioNTech does not currently pay a regular dividend.
Are BioNTech and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.